provided an interesting comparison between passive dosimetry measures and biomonitoring for chlorpyrifos (CP) exposure in pesticide workers. However, they made a questionable assumption of a 3% dermal absorption factor (DAF) for CP, stating: '[The] study by , supports the use of a 3% DAF, the Environmental Protection Agency (EPA) accepted value, whereas Krieger (1995) supports a 10% DAF and report a 1% DAF.' Thus they appear to treat the differences in these three values of 1, 3 and 10% as if they are caused by experimental error because they failed to recognize that the time of exposure is a determining factor for the CP DAF.
Examination of the study by Krieger (1995) shows no experimental data for CP DAF, only a generic range of 0.1-35%/24 h in his Table 2 ; do not show a 3% DAF but a 1.3% average DAF for 12-20 h exposures; Griffin et al. (1995) report an average 1% DAF for an 8 h exposure (Table 1) .
Apparently the 3% value quoted for Nolan et al. may have come from their abstract where they stated, 'less than 3% of the dermal dose [of CP] was excreted in the urine'. EPA apparently took that 3% as the conservative upper estimate for DAF in a risk assessment process, but it is wrong to use it in Geer et al.'s study where they are estimating the actual amount of uptake to compare with urinary output.
Geer et al. report that in their modeled studies 'Each worker was monitored once over a period of time representing a standard work shift [8 h] or duration of application . . . Handwash samples were collected over the monitoring period during times when workers would typically wash their hands (i.e. before meals, before smoking, after using the bathroom, and at the end of the monitoring period) to assess surface deposition on the hands.' Consequently Griffin's data would lead to an expectation that 1% of the hand loading at the start of the study would enter into the skin after 8 h, and assuming the subjects showered or bathed before going to sleep, some 12-20 h after their body exposure, the expectation from Nolan's data is that 1.3% would be absorbed into the skin. Consequently, the authors' usage of 3% for a DAF is very likely to lead to a gross over-prediction of the amount entering the body.
Finally, the authors should have divided each subject's dosage in mg per day by the subject's body mass to provide their CP dosages in units of mg (kg day)
À1
, which could then be compared with EPA's reference dose (RfD) for CP. Failure to divide by body mass distorts these data because, when reported as mg per day, the surface loadings are multiplied by the subject's body surface area (BSA)-and that BSA increases with the subject's weight to the one-half power (Mosteller, 1987) . Thus, if they divided their reported mg per day by the subject's weight, the effect of increasing body mass would be to decrease the mg (kg day)
À1 as opposed to increasing the mg per day.
DAVID T. MAGE
Temple University (retired), Philadelphia, PA, USA E-mail: magedonner@aol.com Table 1 . Experimental CP DAF data of and Griffin et al. (1995) where all subjects in each study received an identical amount of CP placed on their forearms We appreciate Dr Mage's clarification on two points within our article . First, as indicated by Dr Mage, we did attribute dermal absorption factors (DAFs) of 1, 3, and 10% to , /EPA (1999) and Krieger (1995) , respectively. Dr Mage correctly identifies the attribution of 10% to Krieger (1995) as an error. The correct reference (also cited within our article) should be Krieger et al. (2000) . In this work, Krieger et al. do not actually derive or measure a DAF of 10%, but, rather, they justify it for use in their analysis (Table 5) based on the unpublished work of Thongsinthusak, 1991. Dr Mage is correct that do provide a mean DAF estimate of 1.28%. However, we cite and use the 3% value conservatively adopted by EPA based on the work of Nolan et al. Our justification for the use of a 3% DAF is not only based on these references but also on our own findings of a DAF in the range of 3-10% (our Figure 3) . In fact, contrary to Dr Mage's suggestion that 'usage of 3% for a DAF is very likely to lead to a gross over prediction of the amount entering the body,' our results suggest that the 3% value underestimates the actual amount absorbed via the skin. We do not view, nor did we mean to imply, the differences or variability in DAFs as 'experimental error' but rather as inter-study variability due to methodological differences including the time course of exposure and biomarker measurement. This is acknowledged in our current discussion where we state, 'dermal exposure estimates may be prone to uncertainty due to differences in pesticide metabolism in the worker attributable to DURATION and rate of exposure'. Accordingly, this first point of clarification by Dr Mage does not in any way alter our results or conclusions but does provide a point of clarification to our discussion. Dr Mage's second point is that we should have adjusted our dose estimates by the worker's body weight to provide an appropriate metric for comparison with EPA's reference dose. As stated in our introduction, the focus of our research was to 'provide improved understanding of worker exposure and methods of assessment as a fundamental basis for health protection'. Therefore, it was outside the scope of this paper to do as Dr Mage suggests and estimate risk. Our work is intended to provide the exposure assessment underpinning support for such an analysis. For purposes of our stated goal, estimates in units of mg per day provide the appropriate metric.
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